The CD40 ligand (CD40L)-CD40 interaction was initially described to play an essential role during membrane-membrane interactions between activated CD4
1 T lymphocytes and B cells, [1] [2] [3] [4] [5] as well as between CD4 1 T cells and antigenpresenting cells. 6, 7 However, further studies showed that soluble CD40 ligand (sCD40L) produced by T cells and platelets [8] [9] [10] [11] can also exert an important role in immune system regulation, including myeloid progenitor cell development. Bone marrow stromal cells, hematopoietic progenitors, and myeloid progenitors express CD40. Furthermore, the CD40L-CD40 interaction has been shown to influence differentiation of these cells directly and indirectly through regulation of cell proliferation and maturation or through control of the cytokine milieu in the bone marrow, respectively. 10, [12] [13] [14] Macrophages are essential myeloid cells, exhibiting microbicidal activity and regulating inflammatory immune responses. Thus macrophages comprise a pivotal component of the innate immune system. Macrophages express CD40 constitutively, 15, 16 but their functional capability in patients with CD40L deficiency has not been investigated.
Patients with X-linked hyper-IgM syndrome caused by mutations in the gene encoding CD40L (CD40LG) have a broad spectrum of opportunistic infections caused by intracellular bacteria and fungi. These infections resemble infections seen in patients with abnormal myeloid cells, such as those in patients with chronic granulomatous disease (CGD). [17] [18] [19] Although CD40L-deficient patients can experience intermittent neutropenia, they are also susceptible to fatal opportunistic infections, even when neutrophil counts are normal or when receiving granulocyte colony-stimulating factor (G-CSF) and immunoglobulin replacement therapy. 20, 21 These observations indicate that absence of CD40L might impair macrophage function in human subjects and that new therapeutic approaches need to be investigated for optimal treatment of these patients.
Failure to produce IFN-g has been reported in patients with CD40L deficiency. [22] [23] [24] This cytokine primes and activates mature phagocytes. Additionally, IFN-g affects development of progenitor cells to generate mature phagocytes capable of efficiently eliminating opportunistic pathogens. 25 For this reason, recombinant human IFN-g (rhIFN-g) has been used as an adjunctive therapy for patients with CGD 26, 27 and patients with defects in the IL-12/IFNg axis to prevent and treat invasive mycobacterial or fungal infections. However, IFN-g has not been broadly used to treat patients with adaptive primary immunodeficiency disorders. [28] [29] [30] [31] Here we aimed to analyze the in vitro macrophage response in patients with CD40L deficiency with respect to macrophage killing activity, oxidative burst, and production of inflammatory cytokines. Furthermore, we investigated the effects of rhIFN-g and sCD40L treatment on macrophages from CD40L-deficient patients. In addition, we assessed the effect of CD40L deficiency on the macrophage transcriptome before and after rhIFN-g treatment.
METHODS

Case report
An Argentinian CD40L-deficient patient included in our collaborative Latin American Society for Immunodeficiencies (LASID) studies 18 was treated with adjuvant rhIFN-g at the Dr Ricardo Gutierrez Children's Hospital. The hospital is in Argentina, where rhIFN-g (Imukin; Boehringer Ingelheim, Ridgefield, Conn) is already approved for clinical use (Disposicion no. 1265-12). The patient was born to nonconsanguineous family and received BCG vaccine in the first month of life without complication. At 9 months of age, he was given a diagnosis of dysgammaglobulinemia (hyper-IgM syndrome), chronic neutropenia, and pneumonia caused by Pseudomonas species. Conventional treatment for CD40L deficiency (trimethoprim/sulfamethoxazole prophylaxis, intravenous immunoglobulin, and Granulokine) was initiated, and the patient was given a diagnosis of the mutation Q174X in CD40LG (details have been previously reported 18 ). At 5 years of age, he had cervical adrenomegaly caused by mycobacterial disease. The extent and severity of this mycobacterial infection were assessed by means of biopsy, which showed granulomas. Additionally, the PCR result was positive for M tuberculosis complex.
Conventional antituberculosis therapy with a 4-drug regimen (ethambutol, levofloxacin, isoniazid, and rifampicin) was initiated, but the patient had typhlitis requiring surgery. Abundant caseating granulomas were observed in the bowel mucous membrane, requiring colostomy for 6 months, and the patient continued to have refractory mycobacterial disease despite antituberculosis treatment. Therefore simultaneous with the conventional CD40L deficiency and antituberculosis therapy, subcutaneous rhIFN-g (50 mg/m 2 administered 3 times a week) was administrated for 6 months. Under this therapeutic regimen, the patient improved clinically. After that, rhIFN-g therapy was discontinued and isoniazid and rifampicin was continued for 1 additional year until no symptoms of mycobacterial disease were observed. Currently, the patient is 9 years old, has no stem cell donor available, and has had hepatic cryptococcosis.
Subjects
We enrolled 6 CD40L-deficient patients (age range, 3-21 years) from 6 unrelated Brazilian families. Except for the occurrence of M tuberculosis infection in P1, the clinical, immunologic, and genetic characteristics of these patients have been previously described 18 and are summarized in Table E1 in this article's Online Repository at www.jacionline.org. For each experiment, a healthy subject (age range, 23-30 years) was included for comparison. Informed consent was obtained from the patients or their parents and from healthy control subjects. The blood was collected under institutional guidelines, and the study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Institute of Biomedical Sciences, University of São Paulo.
Generation of monocyte-derived macrophages
Human monocyte-derived macrophages (MDMs) were obtained, as previously described, with minor modifications. 32 In summary, CD14 Fig E2. C, MDMs remained untreated or were cultured for 48 hours in the presence of sCD40L (500 ng/mL) or rhIFN-g (100 U/mL); the respiratory burst of MDMs was induced by PMA (90 mmol/L). Cells were analyzed with the luminol-enhanced chemiluminescence assay, and values are expressed as relative light units (RLU). A significant difference is denoted as follows: *P < _ .05 (n 5 6 patients and 6 control subjects), Mann-Whitney test. NS, Not significant.
378C in a humidified 5% CO 2 atmosphere for 5 days in the presence of 50 ng/ mL macrophage colony-stimulating factor (M-CSF; PeproTech, Princeton, NJ). Afterward, the cells underwent phenotypic characterization, including analysis of HLA-DR, CD14, CD40, CD64, CD86, CD80, and CD163. They were also characterized for the following pattern recognition receptors (PRRs): Toll-like receptors (TLRs; TLR1, TLR2, and TLR4) and C-type lectin receptors (CLRs; dectin-1, dectin-3, mannose receptor, CD206, and dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin [DC-SIGN]). Phenotypic expression was analyzed by using flow cytometry (BD FACSCanto II Cytometer). The data obtained were analyzed with FlowJo software (TreeStar, Ashland, Ore). When indicated, MDMs were incubated for 2 more days in the presence of 100 U/mL rhIFN-g (Immukine, Boehringer Ingelheim), 20 ng/mL IL-4 (PeproTech), or 500 ng/mL sCD40L (Life Technologies, Frederick, Md).
Fungicidal activity
MDMs were challenged with Paracoccidioides brasiliensis (Pb18, a highly virulent isolate), and the microbicidal activity was determined by counting colony-forming units (CFU), as previously described. 33 Briefly, 0.2 3 10 5 MDMs were cultured in 200 mL of RPMI 1640 in 96-well flat-bottom plates and challenged with P brasiliensis (ratio 1:10, fungus/MDMs) for 48 hours.
Five days after seeding and challenging, P brasiliensis CFU were counted, and CFU values (percentage of control values) were determined in relation to the CFU numbers of untreated MDMs from healthy control subjects.
Analysis of respiratory burst by means of chemiluminescence
MDM oxidative burst was measured by using luminol-dependent chemiluminescence, as previously described. 34 Luminol (1 mmol/L; Sigma Laboratories, St Louis, Mo)-preloaded MDMs (0.2 3 10 5 /300 mL) were activated with phorbol 12-myristate 13-acetate (PMA; 90 nmol/L, Sigma Laboratories), and chemiluminescence was monitored for 2 hours with a microplate luminometer reader (EG&G Berthold LB96V, Bad Wildbad, Germany). Results were expressed as relative light units.
Analysis of cytokine production
Supernatants of macrophages treated or untreated with rhIFN-g or sCD40L were harvested 48 hours after P brasiliensis or M tuberculosis (lysate) 35 incubation. Cytokine levels were evaluated by using a HCYTMAG-60K-PK30 Cytokine Kit (Millipore, Bedford, Mass), and data obtained were analyzed with a Luminex instrument, according to the manufacturer's instructions. Impaired cytokine production by macrophages from CD40L-deficient patients. Patients' macrophages secrete abnormal levels of IL-6, TNF-a, IL-1b, macrophage inflammatory protein 1b [MIP-1b], IP-10, and G-CSF in response to M tuberculosis and P brasiliensis. After 48 hours of sCD40L (500 ng/mL) or rhIFN-g (100 U/mL) treatment, cytokine production by patients' macrophages achieved a pattern similar to that observed in healthy control subjects. Significant differences are denoted as follows: *P < _ .05 (n 5 6 patients and 6 control subjects), Mann-Whitney test.
IL-1β
Phagocytosis and control of M tuberculosis proliferation by MDMs
Analyses of M tuberculosis (H37Rv strain) phagocytosis and proliferation control by MDMs were carried out, as previously described. 36 In brief, MDMs were challenged at a 1:1 ratio (M tuberculosis/MDMs) for 3 hours (day 0) and washed to remove extracellular mycobacteria. On day 0 and 6 days later, the MDMs were lysed with 0.1% saponin treatment, and the homogenates were diluted and plated in Middlebrook 7H10 medium supplemented with 10% OADC (Difco; acid/albumin/dextrose/catalase). The resultant colonies were assessed after 21 days of incubation at 378C. M tuberculosis uptake (phagocytosis index) data were obtained from CFU counts performed on day 0, and the M tuberculosis growth index was determined based on the ratio of CFU numbers on day 6 to CFU numbers on day 0.
In addition to MDMs, to gain evidence about the role of CD40L-CD40 interaction in myeloid cell development, we analyzed the ability of the promyelocytic HL-60 cell line to control M tuberculosis proliferation by challenging the cells at a 1:1 ratio (M tuberculosis/HL-60 cells). HL-60 cells were only challenged for 3 hours because of rapid HL-60 proliferation. After this, HL-60 cells were lysed, and M tuberculosis proliferation was assessed based on CFU values, as performed for MDMs.
RNA sequencing and data processing
Macrophage transcriptome profiles from 3 CD40L-deficient patients and 3 healthy control subjects were analyzed, as previously described. 32, 37 Total RNA was obtained by using TRIzol (Invitrogen, Carlsbad, Calif), according to the manufacturer's instructions. RNA integrity and concentration were assessed by using the Agilent 2100 Bioanalyser RNA Nano chip (Agilent Technologies, Santa Clara, Calif) and orthogonally validated by means of visualization of the integrity of the 28S and 18S band on an agarose gel. cDNA libraries were obtained with the Illumina CBot station and HiScanSQ using the Illumina TruSeq RNA Sample Preparation Kit (Illumina, San Diego, Calif), according to the manufacturer's instructions. Sequencing was carried out with the Illumina HiSeq 2000 paired-end 100-bp (PE 100) system.
Bioinformatic analysis
After quality assessment with FastQC (www.bioinformatics.babraham.ac. uk/projects/fastqc/), reads were aligned with the human cDNA transcriptome from Ensembl 82 by using Kallisto. 38 Data were further processed by using Sleuth (pachterlab.github.io/sleuth/), and the read values were expressed as transcripts per million. The transcripts with more than 5 reads in each sample for at least 47% of the sample and false discovery rate-adjusted P values (or q values) of less than .05 were considered differentially expressed genes (DEGs). Hierarchical clustering analysis was performed with Perseus (MaxQuant, v1.11, Martinsried, Germany). Gene Ontology (GO) functional enrichment analysis was performed with STRING 39 and DAVID 40, 41 to categorize and group DEGs based on a known functional association, as defined by the Gene Ontology Consortium. 42 GeneMANIA/Cytoscape 43 was used to predict interactions between DEGs by using GO biological process and source organism Homo sapiens as additional parameters.
Statistical analysis
Statistical significance was assessed by using the nonparametric MannWhitney test. Data were expressed as medians and 25th and 75th percentiles. Statistical analyses were performed with GraphPad Prism 4.03 software (GraphPad Software, San Diego, Calif), and P values of .05 or less were considered significant.
RESULTS
MDMs from CD40L-deficient patients have defective fungicidal activity and oxidative burst that are reversed by rhIFN-g but not sCD40L
Based on the morphologic characteristics and expression patterns of the CD14, HLA-DR, CD64, CD163, and CD86 molecules, a homogeneous population of MDMs from CD40L-deficient patients and healthy control subjects was successfully generated (Fig 1, A) . When challenged with P brasiliensis, macrophages from patients demonstrated reduced fungicidal activity compared with those from healthy control subjects (Fig 1, B , and see Fig E1 in this article's Online Repository at www.jacionline. org). Although sCD40L treatment did not significantly increase the killing activity of macrophages from CD40L-deficient patients, rhIFN-g improved the fungicidal activity of macrophages from patients. This finding is consistent with IFN-g's established beneficial therapeutic effect for patients with opportunistic infections and its well-known role as a phagocyte activator.
Considering the essential role of the oxidative burst during macrophages killing activity, 44 we evaluated the production of reactive oxygen species by PMA-activated MDMs from CD40L-deficient patients. Patients' macrophages did not trigger the oxidative burst after activation in comparison with those from healthy subjects (Fig 1, C) . Although sCD40L showed a slight increase in macrophage responses, no significant enhancement was achieved. However, rhIFN-g statistically enhanced the oxidative burst of macrophages in both patients and control subjects. After rhIFN-g treatment, patients' MDMs displayed no significant difference compared with untreated or rhIFN-g-treated MDMs from healthy control subjects. , and the phagocytosis index was determined on day 0 based on CFU counts. B, The bacterial proliferation index on day 6 was determined based on the ratio of CFU numbers on day 6 to CFU numbers on day 0. Data were normalized according to the average mycobacterial growth of untreated MDMs from healthy control subjects. Significant differences are denoted as follows: *P < _ .05 (n 5 6 patients and 6 control subjects), Mann-Whitney test. NS, Not significant. Defective production of inflammatory cytokines by macrophages from CD40L-deficient patients is reversed by rhIFN-g and sCD40L
In addition to responding to invading pathogens by inducing microbicidal activity, macrophages produce inflammatory cytokines in response to CD40L-CD40 interaction. 42 Therefore we analyzed inflammatory cytokines released by MDMs from patients or control subjects treated or untreated with rhIFN-g or sCD40L in response to P brasiliensis. In addition, considering the increased susceptibility to mycobacterial diseases reported in patients with CD40L deficiency, 18, 20, 45 we also challenged the macrophages with M tuberculosis. After 48 hours of culture in the presence of P brasiliensis or M tuberculosis, macrophages from CD40L-deficient patients had significantly impaired production of IL-6, TNF-a, IL-1b, macrophage inflammatory protein 1b, IFN-g-induced protein 10 (IP-10), and granulocytecolony stimulating factor (G-CSF) compared with those of healthy control subjects (Fig 2) . With few exceptions, the impaired cytokine production in CD40L-deficient patients was significantly improved by both rhIFN-g and sCD40L.
Impaired control of M tuberculosis proliferation by macrophages from CD40L-deficient patients is reversed by rhIFN-g
Considering the essential role of IFN-g in the response to mycobacteria 46 and the increased susceptibility to mycobacteria GO:0002376 Immune system process  ACTR2, ADAM10, ADAM15, AP2A2, APP, BAG6,  CANX, CD44, CD46, CTSB, FCGR2B, FLI1,  IGLL5, INPPL1, LGMN, LILRA6, MAP2K3,  MATK, MITF, MYO1F, OSBPL1A, PPP2R4,  TCF12, UBB, ZFP36L1   AOAH, APOBEC3G, APOL1, APOL2, APOL3,  BCL3, BNIP3L, C1QA, C1QB, C1QC, C1R,  C1S, C2, C4A, C4B, C5AR1, CALCOCO2,  CCL8, CD163, CD180, CD40, CD74, CEBPG,  CFB, CIITA, CLIC1, CXCL10, CXCL11,  CXCL9, DHX58, FCGR1A, FCGR1C, GCH1,  HIF1A, HIST2H2BE, HLA-B, HMOX1, IDO1,  IFIH1, IL15, IL27, IL31RA, IL32, IRF7, ITGAL,  LY75, LYN, MMP25, MX1, MX2, NCF1,  NCF1C, NFAM1, NMI, NOD2, P2RX7, PRDX1 18, 20, 45 we asked whether macrophages from CD40L-deficient patients have normal capacity to control the growth of M tuberculosis. Macrophages from CD40L-deficient patients phagocytosed M tuberculosis normally compared with macrophages from healthy control subjects (Fig 3, A) but did not control the intracellular proliferation of M tuberculosis. Most importantly, in accordance with the observation that refractory mycobacterial disease improves with rhIFNg treatment (case report), rhIFN-g significantly increased the control of M tuberculosis proliferation in vitro by macrophages from patients and healthy control subjects (Fig 3, B) .
rhIFN-g improves dysregulation of the macrophage transcriptome in patients with CD40L deficiency
Based on the multiple macrophage functional defects observed in CD40L-deficient patients, we hypothesized that macrophages from CD40L-deficient patients have systemic dysregulation at the gene expression level. Therefore we analyzed the transcriptome of MDMs from CD40L-deficient patients using RNA sequencing and evaluated the effect of rhIFN-g on gene expression. Because it was not possible to collect enough macrophages to stimulate them with both rhIFN-g and sCD40L, we focused on the effect of rhIFN-g because it had the most potential as a new therapeutic option for patients with CD40L deficiency. We based this decision on the previously observed success of rhIFN-g therapy for certain infections, [28] [29] [30] [31] its approval by the US Food and Drug Administration, and its feasibility for clinical use.
We obtained sufficient numbers of MDMs from 3 patients (P1, P2, and P3). Before rhIFN-g treatment, we identified a total of 109 dysregulated genes (DEGs; 48 downregulated and 61 upregulated genes) when macrophages from CD40L-deficient patients were compared with those from healthy control subjects (Fig 4, A, left  panel) . The functional association network of the DEGs in patients with CD40L deficiency is demonstrated in Fig 4, B . Dysregulation of the macrophage transcriptome in patients with CD40L deficiency was not due to M-CSF-induced CD40L effects during MDM generation because M-CSF was unable to induce CD40L expression on MDMs (see Fig E2 in this article' s Online Repository at www.jacionline.org). Furthermore, no CD40L transcript was undetectable by using RNA sequencing. On the other hand, sCD40L increased the capacity of the promyelocytic HL-60 cells to control M tuberculosis proliferation (see Fig E3 in this article' s Online Repository at www.jacionline.org), indicating a role of CD40L-CD40 interaction on myeloid cell development. A detailed investigation about the effect of the CD40L-CD40 interaction on promyelocytic HL-60 cells will be published elsewhere (manuscript in preparation).
It is noteworthy that rhIFN-g restored the gene expression profile of the majority of DEGs in patients' macrophages. After rhIFN-g treatment, only 11 of 109 genes remained differentially expressed in comparison with results seen in healthy control subjects (Fig 4, A, right panel) . In addition to improving the expression of 109 DEGs, rhIFN-g influenced the expression of 526 additional genes (133 downregulated and 393 upregulated genes) compared with that seen in healthy control subjects (Fig 5) . The subsets of 109 DEGs and the additional 526 genes that were affected by the rhIFN-g treatment are shown within GO categories (Table I ). The main subsets of genes are directly involved with the immune system (GO0002376), including the inflammatory response (GO0006954) and wound response (GO0009611). Moreover, genes responsible for regulation of transcription (GO:0010628 and GO:0045892) and cell differentiation (GO:0030154, GO:0000904, GO:0045597, GO:0002521, and GO:0030099) were also affected.
rhIFN-g increases TLR and CLR expression levels
Production of proinflammatory cytokines, oxidative burst, and effective microbicidal activity are essential functions of M1 macrophages, which contrast with M2 macrophages (called alternatively activated macrophages). 47, 48 Despite the functional defects we observed, no phenotypic alteration was identified on macrophages from CD40L-deficient patients. The normal expression of CD86, CD163, and CD206 molecules is shown in Fig E4 in this article's Online Repository at www.jacionline.org, all of which are markers that have been used to distinguish M1/M2 subpopulations. [49] [50] [51] Moreover, macrophages from patients with CD40L deficiency expressed TLRs and CLRs normally (Fig 6) . Remarkably, rhIFN-g significantly increased expression of TLR1, TLR2, dectin-1, and CD209 molecules in macrophages from patients and healthy control subjects.
DISCUSSION
Here we show that human CD40L deficiency impairs innate immune responses by affecting macrophage differentiation and function. Macrophage defects associated with impaired dendritic cell (DC) response in patients with CD40L 22 and CD40 52 deficiencies point to an essential role of the CD40L-CD40 interaction during differentiation of myeloid cells. This fact clarifies a new immunopathologic mechanism underlying the increased susceptibility of CD40L-deficient patients to opportunistic infections, which might explain the increased rate of deaths observed in , TLR (TLR1, TLR2 , and TLR4), and CLR (dectin-1, dectin-3, mannose receptor or MR, DEC-205, and CD209) expression, as analyzed by means of cytometry. MDMs were analyzed after 5 days in the presence of M-CFS, followed by 2 additional days in the presence or absence of rhIFN-g. No significant differences in MDMs from patients versus healthy subjects were observed. *P < _ .05 (n 5 6 patients and 6 control subjects), Mann-Whitney test. NS, Not significant; MFI, Mean fluorescence intensity. patient with CD40L deficiency despite the current treatment armamentarium. 18, 20 The possibility that the differences observed between CD40L-deficient patients and young adult control subjects are age related is unlikely. It is well known that innate immune cells, such as macrophages, from neonates and infants less than 2 years of age have inherent defects; however, older children display immune responses comparable with those of adults. [53] [54] [55] [56] [57] [58] [59] In our diagnostic laboratory we have routinely observed that infants in the first years of life with undefined primary immunodeficiency disorders, in whom the diagnosis of CGD has been ruled out by demonstrating normal NADPH activity, have normal phagocyte responses compared with those in healthy control subjects (data not shown).
Macrophages have to undergo maturation to a stage that allows normal clearance of invading pathogens through different mechanisms, including generation of a fully potent oxidative burst. The importance of this pathway is illustrated by CGD, which is caused by defects affecting components of the phagocyte NADPH oxidase complex that are crucial in oxidative burst. Patients with CGD face life-threatening infections, even when oxidative burst is only slightly reduced or partially inhibited. 17, 60, 61 Therefore the partially defective oxidative burst observed in macrophages from CD40L-deficient patients might contribute to the abnormal microbicidal activity that we demonstrated in our experiments and might be a risk factor for the increased susceptibility to opportunistic fungal and intracellular bacterial infections. However, it seems unlikely that defective fungicidal activity in macrophages from CD40L-deficient patients is solely due to reduced reactive oxygen species production because additional nonoxidative killing mechanisms might also be affected.
The impaired microbicidal activity, oxidative burst, and defective production of cytokines (eg, IL-6, TNF-a, IL-1b, macrophage inflammatory protein 1b, IP-10, and G-CSF) by patients' macrophages suggest that the absence of CD40L not only impairs effector function of macrophages but also initiation of inflammatory responses. These results are in accordance with the proinflammatory role of CD40L-CD40 interaction on activation of macrophages from healthy subjects. 9, 42 The multiple defects identified in macrophages from patients with CD40L deficiency indicate that more than 1 aspect of the macrophage immune response can be affected in these subjects. In accordance with the numerous functional defects displayed by patients' macrophages, we also observed a dysregulated gene expression signature, which was improved in the presence of rhIFN-g. Considering the high number of DEGs in macrophages from CD40L-deficient patients, multiple other functions of these cells remain to be investigated further.
Contradictory results regarding IFN-g production by CD40L-deficient T cells have been reported. However, such incongruences might be explained by the fact that PBMCs/T cells from CD40L-deficient patients are intrinsically capable of producing IL-12 and IFN-g but do not respond to certain stimuli. We found that PBMCs from CD40L-deficient patients normally produce IL-12 in response to IFN-g and release IFN-g in response to IL-12 stimulation (see Fig E5 in this article' s Online Repository at www.jacionline.org). These findings contrast with our previous observation of a significantly impaired IL-12/IFN-g axis 22 in DC/T-cell cocultures stimulated by Candida albicans or P brasiliensis. Both Jain et al 23 and Subauste et al 24 described impaired IFN-g production by PBMCs from CD40L-deficient patients after anti-CD3 stimulation and Toxoplasma gondii exposure, respectively. In contrast, Uronen and Callard 62 reported normal IFN-g release by T cells from CD40L-deficient patients in response to PMA plus ionomycin. In turn, Felipe-Santos et al 63 observed decreased production of IL-12 and IFN-g in response to PHA; however, normal generation of IL-12 by LPS and IFNg by PMA/ionomycin was seen in PBMCs from CD40L-deficient patients compared with generation in healthy control subjects.
The treatment of opportunistic infections in CD40L-deficient patients with rhIFN-g might reduce the high mortality rate associated with CD40L deficiency, despite currently available treatment options. 18, 19, 64, 65 This possibility has been illustrated by the response of one of our CD40L-deficient patients who, despite all the treatment available, had refractory disseminated mycobacterial infection that was improved after rhIFN-g adjuvant therapy. Taken together, our data point to rhIFN-g as a possible adjunct immunotherapy, in combination with conventional therapy, for cases of disseminated opportunistic infections in CD40L-deficient patients. Furthermore, this cytokine is already available and licensed for clinical use. 27, 52, 54 Another mechanism by which rhIFN-g might potentiate macrophage immune responses of macrophages from CD40L-deficient patients is by increasing the expression of TLRs and CLRs, both of which are essential for immune responses against different pathogens.
66 rhIFN-g treatment of macrophages from both patients and control subjects caused significantly increased expression of TLR1, TLR2, dectin-1, and CD209. The potential of IFN-g influencing PRR expression might explain how rhIFN-g can restore microbicidal activity in macrophages from CD40L-deficient patients. However, we did not observe significant changes in TLR1, TLR2, dectin-1, and CD209 mRNA expression after in vitro rhIFN-g treatment in our transcriptome analysis (data not shown). Whether IFN-g regulates the protein expression of these PRRs by modulating mRNA expression at a different time point than those we assessed or whether it acts at a posttranscriptional level requires further investigation.
In conclusion, our data demonstrated that in the absence of the CD40L-CD40 interaction, macrophages from CD40L-deficient patients exhibit impaired function and differentiation because of dysregulation of gene expression that might contribute to their susceptibility to opportunistic infections. Furthermore, rhIFN-g might represent a new therapeutic option for patients with CD40L deficiency by restoring certain functions to macrophages.
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Clinical implications: The absence of CD40L impairs macrophage differentiation and function, and its lack contributes to increased susceptibility of CD40L-deficient patients to lifethreatening infections. Furthermore, rhIFN-g improves the function of macrophages from CD40L-deficient patients, indicating this cytokine as a potential new adjuvant therapy. . rhIFN-g, but not sCD40L, improves the defective fungicidal activity seen in CD40L-deficient patients. A, After challenging MDMs with P brasiliensis, fungicidal activity was assessed by determining CFU values. Before assay, MDMs were either untreated (2) or treated with (1) sCD40L (500 ng/ mL) or rhIFN-g (100 U/mL) for 48 hours. CFU values (percentage of control values) were determined in relation to the CFU number of untreated MDMs from healthy control subjects. B, Raw data in CFU/mL are also shown. Significant differences are denoted as follows: *P < _ .05 (n 5 6 patients and 6 control subjects), Mann-Whitney test. Patient P4 recently died in a cachectic state after recurrent diarrhea caused by Cryptosporidium species infection and concomitant severe mycobacterial tuberculosis infection. Therefore his macrophages were not analyzed for CD86, CD163, and CD206 or PRR expression, respectively, as shown in Fig E4 and Fig 6. 
